Enterprise Value
15.37M
Cash
78.02M
Avg Qtr Burn
-41.91M
Short % of Float
0.77%
Insider Ownership
31.19%
Institutional Own.
23.19%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CAEL-101 Details Amyloid light chain amyloidosis | BLA Submission | |
CUTX-101 (Copper Histidinate) Details Menkes Disease , Blood cancer | NDA Submission | |
Triplex Details Cytomegalovirus | Phase 2 Data readout | |
Dotinurad Details Chronic refractory gout | Phase 1b Initiation | |
CEVA-101 Details Traumatic brain injury | Failed Discontinued |